Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic

Influence of Morbid Obesity on the Clinical Pharmacokinetics of Various Anti-Infective Drugs

(2018) Nuggehally R. Srinivas   AMERICAN JOURNAL OF THERAPEUTICS

Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014)

(2016) Ronald N. Jones et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimizing the Clinical Use of Vancomycin

(2016) Rocío Álvarez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dalbavancin for the treatment of paediatric infectious diseases

(2016) S. Esposito et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia

(2016) Liapikou Adamantia et al.   Expert Opinion on Drug Metabolism & Toxicology

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013)

(2016) Michael D. Huband et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides

(2016) Matthew P. Crotty et al.   JOURNAL OF CLINICAL MICROBIOLOGY

New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents

(2016) Andrew W. Hahn et al.   MEDICAL CLINICS OF NORTH AMERICA

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

(2016) Kimberly Leuthner et al.   Therapeutics and Clinical Risk Management

Antibiotic drug discovery

(2016) Wolfgang Wohlleben et al.   Microbial Biotechnology

Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue

(2015) Michael W. Dunne et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects

(2015) Patrick J. Scoble et al.   CLINICAL DRUG INVESTIGATION

Beyond Vancomycin: The Tail of the Lipoglycopeptides

(2015) Kenneth P. Klinker et al.   CLINICAL THERAPEUTICS

Translational deficiencies in antibacterial discovery and new screening paradigms

(2015) Paul M Dunman et al.   CURRENT OPINION IN MICROBIOLOGY

Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

(2015) Lesley J. Scott   DRUGS

Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of Age

(2015) John S. Bradley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?

(2013) Andrew A. Udy et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model

(2013) Daniela Baldoni et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

New Lipoglycopeptides

(2010) George G. Zhanel et al.   DRUGS

Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment

(2009) Thomas Marbury et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin

(2009) Michael T Guskey et al.   PHARMACOTHERAPY

Dalbavancin: A new lipoglycopeptide antibiotic

(2008) J. Bailey et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic

(2008) James A. Dowell et al.   JOURNAL OF CLINICAL PHARMACOLOGY